Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Champions Oncology Inc (CSBR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Champions Oncology's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
10.460 0.000    0.00%
24/09 - Closed. Currency in USD ( Disclaimer )
After Hours
10.490
+0.060
+0.575%
16:00:00 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US15870P3073 
CUSIP:  15870P307
  • Volume: 11,273
  • Bid/Ask: 9.880 / 11.280
  • Day's Range: 10.342 - 10.510
Champions Oncology 10.460 0.000 0.00%
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

194

Equity Type

ORD

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.

Contact Information

Phone +1-410-3690365
Fax 302-6365454

Top Executives

Name Age Since Title
Joel Ackerman 56 2010 Chairman of the Board
Ronnie Morris 55 2010 President, CEO & Director
Manuel Hidalgo 53 2007 Scientific Advisor
David Sidransky 61 2007 Independent Lead Director
René Bernards 68 - Scientific Advisor
Scott R. Tobin 50 2011 Independent Director
Daniel N. Mendelson 56 2013 Independent Director
Harvey I. Pass - - Scientific Advisor
Misti Ushio 50 - Board Observer
Justin Stebbing - - Scientific Advisor
Philip P. Breitfeld 68 2016 Chief Strategy & Innovation Officer and Independent Director
Philip P. Breitfeld 68 2016 Chief Strategy & Innovation Officer and Independent Director
Philip P. Breitfeld 68 2016 Chief Strategy & Innovation Officer and Independent Director
Philip P. Breitfeld 68 2016 Chief Strategy & Innovation Officer and Independent Director
Robert Brainin 50 2021 Independent Director
Robert Brainin 50 2021 Independent Director
Robert Brainin 50 2021 Independent Director
Robert Brainin 50 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CSBR Comments

Write your thoughts about Champions Oncology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email